1:26-cv-00886
Boehringer Ingelheim Pharma Inc v. Centaur Pharma Pvt Ltd
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Boehringer Ingelheim Pharmaceuticals Inc. (Delaware); Boehringer Ingelheim International GmbH (Germany); Boehringer Ingelheim Pharma GmbH & Co. KG (Germany)
- Defendant: Centaur Pharmaceuticals Pvt. Ltd. (India)
- Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
- Case Identification: 1:26-cv-00886, D. Del., 07/20/2026
- Venue Allegations: Venue is alleged to be proper because the Defendant is an Indian corporation not residing in any U.S. district and has previously availed itself of legal protections in the District of Delaware.
- Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA, seeking to market a generic version of Plaintiff's TRADJENTA® (linagliptin) tablets, constitutes an act of infringement of four U.S. patents.
- Technical Context: The technology relates to pharmaceutical compositions and methods for treating type 2 diabetes mellitus using a dipeptidyl peptidase-4 (DPP-IV) inhibitor, a significant class of oral antidiabetic drugs.
- Key Procedural History: This is a Hatch-Waxman action initiated within 45 days of Plaintiff's receipt of a Paragraph IV certification letter from the Defendant, dated on or about June 11, 2026. This filing triggers a potential 30-month stay of FDA approval for the Defendant's generic product.
Case Timeline
| Date | Event |
|---|---|
| 2006-05-04 | U.S. Patent No. 11,033,552 Priority Date |
| 2008-08-07 | U.S. Patent No. 9,486,526 Priority Date |
| 2008-10-16 | U.S. Patent No. 11,911,388 Priority Date |
| 2009-08-05 | U.S. Patent No. 10,034,877 Priority Date |
| 2016-11-08 | U.S. Patent No. 9,486,526 Issue Date |
| 2018-07-31 | U.S. Patent No. 10,034,877 Issue Date |
| 2021-06-15 | U.S. Patent No. 11,033,552 Issue Date |
| 2024-02-27 | U.S. Patent No. 11,911,388 Issue Date |
| 2026-06-11 | Plaintiff receives Paragraph IV certification letter from Defendant (approximate) |
| 2026-07-20 | Complaint Filing Date |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 9,486,526 - "Treatment for Diabetes in Patients Inappropriate for Metformin Therapy"
Issued November 8, 2016 (the "'526 Patent")
The Invention Explained
- Problem Addressed: The patent describes the need for effective diabetes treatments for patients who cannot take metformin, a first-line therapy, due to contraindications or intolerability, particularly those with renal impairment '526 Patent, col. 2:1-5 Standard treatments may be unsuitable or require dose adjustments in this population '526 Patent, col. 1:24-38
- The Patented Solution: The patent proposes a method of treating type 2 diabetes in this specific metformin-ineligible patient population by administering a 5 mg daily oral dose of the DPP-4 inhibitor linagliptin '526 Patent, abstract '526 Patent, col. 8:3-10 The invention is presented as a safe and effective treatment option for patients with moderate to severe renal impairment without requiring dose adjustment '526 Patent, col. 14:15-25
- Technical Importance: This method provides a simplified and predictable treatment regimen for a clinically complex patient subgroup that often requires careful medication management due to comorbidities like renal disease.
Key Claims at a Glance
- The complaint asserts at least one claim, providing claim 1 as representative Compl. ¶41
- Independent Claim 1 of the '526 Patent includes these essential elements:
- A method for treating and/or preventing type 2 diabetes mellitus in a patient having moderate or severe chronic renal impairment or end-stage renal disease;
- comprising orally administering to the patient a DPP-4 inhibitor, which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine (linagliptin) or a salt thereof;
- wherein said DPP-4 inhibitor is administered in an oral dose of 5 mg per day; and
- wherein metformin therapy for said patient is ineligible due to contraindication against metformin.
U.S. Patent No. 10,034,877 - "Treatment for Diabetes in Patients Inappropriate for Metformin Therapy"
Issued July 31, 2018 (the "'877 Patent")
The Invention Explained
- Problem Addressed: Similar to the '526 Patent, this patent addresses the treatment of diabetes patients for whom metformin is inappropriate. It specifically notes that such patients, particularly those with renal impairment, are at increased risk for complications '877 Patent, col. 1:19-23 '877 Patent, col. 2:1-5
- The Patented Solution: The patent claims a method of administering a 5 mg daily dose of linagliptin to patients with one or more specific contraindications to metformin (e.g., renal disease, congestive heart failure). A key aspect of the solution is that no dose adjustment of the linagliptin is required for patients who also have renal impairment, simplifying the treatment regimen '877 Patent, abstract '877 Patent, col. 14:1-14
- Technical Importance: The invention provides a fixed-dose therapeutic option that is suitable for patients with a variety of common comorbidities, potentially reducing the complexity of prescribing for physicians.
Key Claims at a Glance
- The complaint asserts at least one claim, providing claim 1 as representative Compl. ¶43
- Independent Claim 1 of the '877 Patent includes these essential elements:
- A method of treating metabolic diseases in a patient for whom metformin therapy is inappropriate due to at least one contraindication against metformin;
- comprising orally administering to the patient 5 mg of linagliptin per day;
- wherein the contraindication is selected from the group consisting of: renal disease, renal impairment or renal dysfunction, unstable or acute congestive heart failure, acute or chronic metabolic acidosis, and hereditary galactose intolerance; and
- wherein no adjustment of the daily dose is required for linagliptin in a patient with mild, moderate or severe renal impairment or end-stage renal disease.
U.S. Patent No. 11,033,552 - "DPP IV Inhibitor Formulations"
Issued June 15, 2021 (the "'552 Patent")
Technology Synopsis
The patent addresses technical challenges in creating stable solid-form pharmaceutical compositions of DPP-IV inhibitors, noting that the active ingredient's amino group can react with common excipients and their impurities, especially in low-dosage forms '552 Patent, col. 1:25-45 The patented solution is a specific formulation comprising the active ingredient linagliptin (at 0.5-7.0% by weight) combined with a particular set of excipients: mannitol (first diluent), pregelatinized starch (second diluent), copovidone (binder), corn starch (disintegrant), and magnesium stearate (lubricant) '552 Patent, claim 1
Asserted Claims
The complaint asserts at least one claim, providing claim 1 as representative Compl. ¶45
Accused Features
The complaint alleges on information and belief that the Centaur ANDA Product is a solid-form pharmaceutical composition containing 5 mg of linagliptin and other excipients, such that it would infringe the claims of the '552 Patent Compl. ¶46
U.S. Patent No. 11,911,388 - "Treatment for Diabetes in Patients with Insufficient Glycemic Control Despite Therapy with an Oral or Non-oral Antidiabetic Drug"
Issued February 27, 2024 (the "'388 Patent")
Technology Synopsis
This patent addresses the treatment of patients whose type 2 diabetes is not adequately controlled despite being on existing antidiabetic therapies, such as metformin or insulin '388 Patent, col. 1:19-35 The invention provides a method for improving glycemic control in this patient population by administering 5 mg of linagliptin as an add-on therapy in combination with the existing treatment regimen '388 Patent, abstract
Asserted Claims
The complaint asserts at least one claim, providing claim 1 as representative Compl. ¶47
Accused Features
The complaint alleges that the proposed prescribing label for the Centaur ANDA Product will instruct healthcare providers to administer linagliptin as a combination therapy for patients with insufficient glycemic control, thereby causing infringement of the '388 Patent Compl. ¶48
III. The Accused Instrumentality
Product Identification
The accused instrumentality is Defendant Centaur's proposed generic 5 mg linagliptin tablets, which are the subject of Abbreviated New Drug Application No. 221520 (the "Centaur ANDA Product") Compl. ¶9
Functionality and Market Context
The Centaur ANDA Product is a proposed generic version of Plaintiffs' TRADJENTA® product Compl. ¶1 As an ANDA product, it is intended to be bioequivalent to the brand-name drug Compl. ¶33 The complaint alleges that the infringement occurs through two pathways: 1) for the composition patent, the manufacture and sale of the physical tablet Compl. ¶46, and 2) for the method patents, the use of the product in accordance with instructions that will allegedly be included in its prescribing label, which will cause healthcare providers to practice the patented methods Compl. ¶42 Compl. ¶44 Compl. ¶48
IV. Analysis of Infringement Allegations
The complaint outlines infringement theories for four patents. For the method-of-use patents ('526, '877, and '388), the central allegation is that Centaur's proposed product label will induce infringement by instructing physicians to prescribe the drug for the claimed patient populations and uses (Compl. ¶54; Compl. ¶55). For the composition patent ('552), the infringement theory is based on the alleged formulation of the physical product itself Compl. ¶46 The complaint includes a diagram of the chemical structure for linagliptin, the active ingredient in both the patented methods and the accused product Compl. ¶45
'526 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method for treating and/or preventing type 2 diabetes mellitus in a patient having moderate or severe chronic renal impairment or end-stage renal disease | The complaint alleges that the proposed prescribing label for the Centaur ANDA Product will instruct its use in patients with type 2 diabetes and moderate or severe chronic renal impairment or end-stage renal disease. | ¶42 | col. 10:1-10 |
| comprising orally administering to the patient a DPP-4 inhibitor, which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine or a pharmaceutically acceptable salt thereof | The Centaur ANDA Product is an oral tablet containing 5 mg of linagliptin, the specified DPP-4 inhibitor. | ¶42 | col. 8:15-28 |
| wherein said DPP-4 inhibitor is administered in an oral dose of 5 mg per day to said patient | The Centaur ANDA Product is a 5 mg tablet, and its label will allegedly instruct for once-daily administration. | ¶42 | col. 8:3-5 |
| wherein metformin therapy for said patient is ineligible due to contraindication against metformin. | The complaint alleges the product's instructions will direct its use for patients who are ineligible for metformin therapy. | ¶42 | col. 2:1-5 |
'877 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method of treating metabolic diseases in a patient for whom metformin therapy is inappropriate due to at least one contraindication against metformin comprising orally administering to the patient 5 mg of...xanthine per day | The complaint alleges the product label will instruct the use of the 5 mg linagliptin tablet in patients for whom metformin therapy is inappropriate. | ¶44 | col. 9:55-65 |
| wherein the contraindication is selected from the group consisting of: renal disease, renal impairment or renal dysfunction, unstable or acute congestive heart failure, acute or chronic metabolic acidosis, and hereditary galactose intolerance | The complaint alleges the proposed label will direct use in patients with these specific contraindications. | ¶44 | col. 1:65-2:5 |
| wherein no adjustment of the daily dose is required for...xanthine in a patient with mild, moderate or severe renal impairment or end-stage renal disease. | The complaint alleges the proposed label will instruct administration of linagliptin without dose adjustment in this patient population. | ¶44 | col. 14:1-14 |
Identified Points of Contention
- Scope Questions: The core of the dispute for the method patents will be whether Centaur's proposed product label, as it will be finally approved by the FDA, will contain instructions that actively induce physicians to perform all the steps of the claimed methods. This raises the question of how closely the label must track the claim language to constitute inducement.
- Technical Questions: For the '552 composition patent, the analysis will depend on the specific formulation detailed in Centaur's confidential ANDA filing. The complaint provides little detail on the accused product's excipients Compl. ¶36, so a key question will be whether the accused formulation literally meets the claim limitations regarding the identity and concentration of its components, or if an analysis under the doctrine of equivalents will be necessary.
V. Key Claim Terms for Construction
The Term: "inappropriate due to at least one contraindication against metformin" (['877 Patent, claim 1](https://ex:cit:39)) and "ineligible due to contraindication against metformin" (['526 Patent, claim 1](https://ex:cit:40)).
Context and Importance
The definition of these terms is central to defining the scope of the patient population covered by the method claims. The infringement analysis for these patents will hinge on whether Centaur's proposed label instructs use for a patient population that falls within the court's construction of "inappropriate" or "ineligible."
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The specifications of both patents provide general discussions about metformin intolerance and contraindications, which could support a broad, functional definition not limited to a specific list of conditions '877 Patent, col. 2:1-5
- Evidence for a Narrower Interpretation: Claim 1 of the '877 Patent explicitly recites a Markush group of specific contraindications, which may be argued to limit the scope of "inappropriate" in that patent. Furthermore, descriptions of specific patient groups in clinical trials discussed in the specification could be used to argue for a narrower definition tied to those examples '877 Patent, col. 28:25-33
The Term: "no adjustment of the daily dose is required" (['877 Patent, claim 1](https://ex:cit:39)).
Context and Importance
This negative limitation is a critical element of the claimed method in the '877 Patent. For infringement to occur, Centaur's proposed label must either explicitly state or implicitly encourage the administration of the 5 mg dose to renally impaired patients without reduction. Practitioners may focus on this term because it distinguishes the invention from other treatments that do require dose adjustments.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The term itself is straightforward, and a party might argue it should be given its plain and ordinary meaning: that the standard dose is maintained.
- Evidence for a Narrower Interpretation: The patent specification describes the pharmacokinetic profile of linagliptin, noting its non-renal elimination pathway, as the scientific basis for why no dose adjustment is needed '877 Patent, col. 14:1-25 '877 Patent, col. 23:7-21 This technical context could be used to define the term in the specific context of the drug's properties.
VI. Other Allegations
Indirect Infringement
The complaint alleges induced infringement for the method patents ('526, '877, '388), stating that Centaur's proposed prescribing label will affirmatively instruct and encourage healthcare providers to use the Centaur ANDA Product in a manner that directly infringes the claims Compl. ¶54 Compl. ¶63 Compl. ¶84 For the composition patent ('552), the complaint alleges contributory infringement, asserting the Centaur ANDA product is not a staple article of commerce and is especially made for an infringing use Compl. ¶¶73-74, as well as induced infringement based on labeling instructions Compl. ¶76
Willful Infringement
The complaint alleges that Centaur had "actual knowledge" of the patents-in-suit, as evidenced by its submission of a Paragraph IV certification letter Compl. ¶54 Compl. ¶63 Compl. ¶75 Compl. ¶84 Based on this alleged pre-suit knowledge, the complaint asserts that this is an "exceptional case" warranting an award of enhanced damages and attorneys' fees Compl. ¶57 Compl. ¶66 Compl. ¶78 Compl. ¶87
VII. Analyst's Conclusion: Key Questions for the Case
- A core issue will be one of induced infringement: Will the final, FDA-approved prescribing label for Centaur's generic product contain language that actively encourages or instructs physicians to prescribe it for the specific patient populations and methods of use recited in the asserted method claims, or will it be a "skinny label" that carves out these patented uses?
- A key evidentiary question will be one of compositional identity: Does the formulation detailed in Centaur's confidential ANDA submission literally meet the specific combination and concentration of excipients required by the '552 composition patent, or will the dispute center on whether any formulation differences are insubstantial under the doctrine of equivalents?
- A foundational issue for the case will be patent validity: Can the asserted claims, which are directed to new methods of use and formulations of a known compound (linagliptin), withstand challenges of obviousness based on the state of the art at the time of invention?